Grand challenges in diabetes.

Aaron Vinik

doi:10.3389/fendo.2012.00037

Abstract

Grand challenges in diabetes.

Highlights

In the treatment of diabetes, we have come a long way from the once dearth of agents that at one time included only insulin, sulfonylureas and the biguanides
Less than one third of patients with diabetes are at their management targets of their glycemic control, a number which plummets further to
Three major studies – ADVANCE, ACCORD, and VADT – taught us that intensification of glycemic control in people at great risk for macrovascular complications does not achieve a reduction in major adverse cardiovascular events (MACE; Boussageon et al, 2011; Bennett et al, 2012)

Summary

Introduction

In the treatment of diabetes, we have come a long way from the once dearth of agents that at one time included only insulin, sulfonylureas and the biguanides. Less than one third of patients with diabetes are at their management targets of their glycemic control, a number which plummets further to

Results

Conclusion